Soheil Aghamohammadzadeh, PhD

Soheil joins Lysoway with more than 10 years of experience in small molecule drug discovery targeting multiple therapeutic areas including neuroscience, respiratory, and dermatology. He has experience working across large pharmaceutical companies like Pfizer and small biotech companies like Proteostasis Therapeutics and Eloxx Pharmaceuticals. He comes with the expertise of transitioning 4 molecules from early discovery to clinic.

At Eloxx Pharmaceuticals, Soheil was a project lead for two rare disease programs including cystic fibrosis (CF) and recessive dystrophic epidermolysis bullosa (RDEB). At Eloxx, he was instrumental in writing and receiving a $2.6M grant from the CF foundation to develop therapies for CF patients. Prior to Eloxx, he was a pharmacology lead at Proteostasis Therapeutics where he managed a team that generated IND enabling data packages for 3 clinical candidates.

Soheil holds a PhD in Cell Biology from Sheffield University (UK) and completed his postdoctoral fellowship at Pfizer Neuroscience Research Unit. His focus at Pfizer was on the dysfunction of the protein degradation pathway in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Soheil is passionate about drug discovery, with the aim to provide disease modifying therapies for patients with unmet medical need.